Evidence map›Paper›PMID 33381199›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2020

Complementary and Alternative Medicines for the Treatment of Hepatitis C: Perspectives of Users and CAM Practitioners.

Salamat Ali, Shahan Ullah, Vibhu Paudyal, Mashhood Ali, Muhammad Khalid Tipu, Tofeeq Ur-Rehman

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Salamat Ali *Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.ORCID https://orcid.org/0000-0003-0280-3299
Shahan Ullah *Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.ORCID https://orcid.org/0000-0003-4597-8902
Vibhu PaudyalSchool of Pharmacy, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0002-4173-6490
Mashhood AliDepartment of Gastroenterology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan.ORCID https://orcid.org/0000-0001-6064-7592
Muhammad Khalid TipuDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.ORCID https://orcid.org/0000-0003-2041-9557
Tofeeq Ur-RehmanDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.ORCID https://orcid.org/0000-0003-4904-1367
Quaid-i-Azam University · PKPakistan Institute of Medical Sciences · PKUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite substantial progress in the treatment of hepatitis C through the use of direct-acting antivirals which have been shown to cure the disease, complementary and alternative medicines (CAM) are popular among patients as a substitute or complement of allopathic medicines. This study aimed to explore the perspectives of patients and CAM practitioners on the use of CAM for the treatment of hepatitis C in Pakistan.

methodsA cross-sectional design was adopted. Participants (CAM practitioners and patients) were recruited from the capital and two provinces: Khyber Pakhtunkhwa and Punjab of Pakistan. A survey using paper-based questionnaires, each specific for patients and CAM practitioners, was conducted to gather information pertaining to demography, disease status, treatment history, and participants' perspectives (about the disease, reasons to switch to CAM, and referring source).

resultsA total of 417 respondents (

conclusionsPatients' beliefs in CAM, side effects of allopathic therapy, high cost of allopathic medicines, and referrals from previous CAM users are key factors in the switching of hepatitis C patients to CAM.

Identifiers

PMID33381199
PMCPMC7755471
OpenAlexW3111334591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.